| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥1.39 |
| 52 Week High | CN¥2.55 |
| 52 Week Low | CN¥1.38 |
| Beta | 0.67 |
| 1 Month Change | -16.27% |
| 3 Month Change | -13.67% |
| 1 Year Change | -48.19% |
| 3 Year Change | -71.41% |
| 5 Year Change | -54.23% |
| Change since IPO | -47.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 08HH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.3% | 2.5% | 1.8% |
| 1Y | -48.2% | -27.7% | 2.2% |
Return vs Industry: 08HH underperformed the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: 08HH underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 08HH volatility | |
|---|---|
| 08HH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 08HH has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 08HH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 40,370 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
| 08HH fundamental statistics | |
|---|---|
| Market cap | €7.01b |
| Earnings (TTM) | €308.18m |
| Revenue (TTM) | €5.35b |
25.5x
P/E Ratio1.5x
P/S RatioIs 08HH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 08HH income statement (TTM) | |
|---|---|
| Revenue | CN¥41.40b |
| Cost of Revenue | CN¥21.72b |
| Gross Profit | CN¥19.68b |
| Other Expenses | CN¥17.30b |
| Earnings | CN¥2.39b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 0.89 |
| Gross Margin | 47.54% |
| Net Profit Margin | 5.76% |
| Debt/Equity Ratio | 57.7% |
How did 08HH perform over the long term?
See historical performance and comparison